Utah Administrative Code
The Utah Administrative Code is the body of all effective administrative rules as compiled and organized by the Division of Administrative Rules (see Subsection 63G-3-102(5); see also Sections 63G-3-701 and 702).
NOTE: For a list of rules that have been made effective since January 1, 2020, please see the codification segue page.
NOTE TO RULEFILING AGENCIES: Use the RTF version for submitting rule changes.
R384. Health, Disease Control and Prevention; Health Promotion.
Rule R384-210. Co-prescription Guidelines -- Reporting.
As in effect on January 1, 2020
Table of Contents
- R384-210-1. Authority and Purpose.
- R384-210-2. Guidelines for the Issuance of a Prescription for an Opioid Antagonist Along with a Prescription for an Opioid.
- Date of Enactment or Last Substantive Amendment
- Authorizing, Implemented, or Interpreted Law
This rule establishes scientifically based guidelines for controlled substance prescribers to co-prescribe an opiate antagonist to a patient pursuant to Section 26-55-108.
R384-210-2. Guidelines for the Issuance of a Prescription for an Opioid Antagonist Along with a Prescription for an Opioid.
(1) Co-prescribing guidelines are applicable when prescribing opioids.
(2) Prescribers are encouraged to co-prescribe and opioid antagonist, such as naloxone; and to provide education on how to recognize an opioid overdose to patients, patient's household members and/or close contacts, when available, if factors exist that increase risk for opioid overdose, and households where preschool age children live or visit, whenever opiate medication is prescribed. Risks for opioid overdose include:
(a) a known history of overdose;
(b) a known history of substance use disorder;
(c) a mental health condition that could make a patient susceptible to overdose;
(d) a risk for returning to a high dose to which they are no longer tolerant (e.g., patients recently released from prison);
(e) unstable medical conditions, such as respiratory disease, sleep apnea, cognitive decline medical conditions, or other comorbidities that make a patient susceptible to opioid toxicity, respiratory distress or overdose;
(f) higher opioid dosages such as a dose greater than or equal to 50 Morphine Milligram Equivalents/day; and
(g) concurrent benzodiazepine use.
naloxone, opioid antagonist, co-prescribing
June 7, 2018
For questions regarding the content or application of rules under Title R384, please contact the promulgating agency (Health, Disease Control and Prevention; Health Promotion). A list of agencies with links to their homepages is available at http://www.utah.gov/government/agencylist.html or from http://www.rules.utah.gov/contact/agencycontacts.htm.